Decreased detection of ESBL- or pAmpC-producing *Escherichia coli* in broiler breeders imported into Sweden

Oskar Nilsson1, Stefan Börjesson1,2*, Annica Landén1, Christina Greko1 and Björn Bengtsson1

**Abstract**

In the spring of 2010, it was discovered that a large proportion of broilers in Sweden were colonized with *Escherichia coli* producing extended-spectrum beta-lactamases (ESBL) or plasmid mediated AmpC (pAmpC). It was hypothesized that the high prevalence was due to transfer from an upper level in the production pyramid and sampling upwards in the production pyramid was initiated. From 2010 to 2019, all shipments (n = 122) of broiler breeders were screened on arrival to Sweden for the occurrence of ESBL- or pAmpC-producing *E. coli* using selective methods. Samples of paper linings from shipments of breeders were cultured on MacConkey agar supplemented with cefotaxime (1 mg/L) after pre-enrichment in either MacConkey broth with cefotaxime (1 mg/L), or from late June 2015 in buffered peptone water without antibiotics. ESBL- or pAmpC-producing *E. coli* was isolated from 43 (35%) of these. Over the years, the proportion of positive imports have decreased and during 2018 and 2019 all imports were negative. In conclusion, the occurrence of ESBL- or pAmpC-producing *E. coli* in broiler breeders on arrival to Sweden has decreased. Such bacteria have not been detected in any shipments since 2017.

**Keywords:** Antibiotic resistance, Chickens, Spread

**Findings**

Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBL) and plasmid-mediated AmpC (pAmpC) are a problem in human clinical settings due to their ability to hydrolyse third generation cephalosporins. There are also indications of potential spread from food producing animals to humans, although of limited importance in Sweden [1, 2]. Due to the risk of spread from animals to humans via food, the occurrence of *Escherichia coli* with resistance to extended spectrum cephalosporins in caecal samples from broilers has since 2010 been investigated with selective culture methods within the Swedish veterinary antimicrobial resistance monitoring program (Svarm) [3]. In the spring of 2010, it was discovered within the framework of Svarm, that a large proportion of broilers in Sweden was colonized with ESBL- or pAmpC-producing *E. coli* (Fig. 1). Following this finding, the National Veterinary Institute (SVA), in cooperation with the Swedish Poultry Meat Association (SPMA) and the two broiler breeding companies in Sweden started to investigate the sources and reasons for the high prevalence. As the use of antibiotics for broilers in Sweden is low, with less than 1% of raised flocks being treated each year, selection by use of antibiotics was not considered a likely cause [3]. Extended spectrum cephalosporins are not used at all for broilers or broiler breeders in Sweden. Instead, it was hypothesised that the high occurrence was due to transfer from higher level in the production pyramid, as has previously been suggested for other types of antibiotic resistant *E. coli* [4, 5]. Therefore, in the late spring of 2010, sampling upwards in the production pyramid was initiated, starting with environmental samples from the sorting bands in broiler...
hatcheries and later in hatcheries for parent birds. ESBL- or pAmpC-producing \textit{E. coli} were isolated from both broiler and parent hatcheries indicating introduction via imported day-old breeding stock and subsequent spread vertically and longitudinally in the Swedish broiler production. This hypothesis was reinforced by the findings in a study on vertical transmission conducted from July 2010 to August 2011 \cite{6}. The role of imported breeders for the occurrence of ESBL- or pAmpC producing \textit{E. coli} in national broiler productions has also be demonstrated in other countries \cite{7, 8, 9, 10}.

As of August 2010, samples of paper linings from all shipments of breeders imported into Sweden by the companies associated to the Swedish Poultry Meat Association (SPMA) have been cultured for ESBL- or pAmpC-producing \textit{E. coli} using selective methods. According to the protocol suggested by EFSA for monitoring of ESBL- or pAmpC-producing \textit{E. coli} in livestock (www.eurl-ar.eu), adjustments were made in regard to the methodology of the surveillance of imported breeders. Initially all samples were cultured on MacConkey agar with ceftaxime (1 mg/L) after pre-enrichment in MacConkey broth with ceftaxime (1 mg/L), but from late June 2015, the pre-enrichment was changed to buffered peptone water without antibiotics. Suspected ceftaxime resistant \textit{E. coli} were sub-cultured on horse blood agar and verified as \textit{E. coli} by indole test. Detection of genes encoding ESBL- or pAmpC was done using polymerase chain reaction analysis \cite{11–13}.

From August 2010 to December 2019, 1299 samples of paper linings from breeders originating from 122 shipments have been cultured. At least one sample per breeder line and source farm was sampled, resulting in 4 to 26 samples per shipment. In total, ESBL- or pAmpC-producing \textit{E. coli} was isolated from 195 samples (15%) from 43 (35%) of the shipments. The proportion of samples and shipments positive for ESBL- or pAmpC-producing \textit{E. coli} has varied between the years (Fig. 2 and Table 1), but as of 2017 to 2019 only one shipment has been positive for ESBL- or pAmpC-producing \textit{E. coli}. In general, there has been a decreasing trend since 2010 except for a large increase in positive shipments and samples in 2015. The reason for this temporary increase remains unknown but it was not due to the shift in methodology in June 2015 as the increase was noticed already at the end of 2014, i.e. before the change in methodology. More precisely, between August 2014 to June 2015, 11 out of 14 shipments of breeders where positive for ESBL- or pAmpC-producing \textit{E. coli}. The majority of the isolates carried genes belonging to the \textit{bla\textsubscript{CMY}}-group (\(n=146\)). The remaining isolates carried a gene in the \textit{bla\textsubscript{CTX-M-1}}-group (\(n=36\)), or \textit{bla\textsubscript{SHV}} -group (\(n=7\)). Six isolates from two shipments where lost and not available for confirmation. However, the occurrence of pAmpC-producing \textit{E. coli} carrying genes belonging to the \textit{bla\textsubscript{CMY}}-group in the birds from these shipments has been confirmed in subsequent sampling with boot swabs in these flocks (data not shown). Therefore, the original isolates and shipments are considered as ESBL- or pAmpC-positive.

Historically, isolates from the Swedish broiler production with a gene in the \textit{bla\textsubscript{CMY}}-Group all carried \textit{bla\textsubscript{CMY-2}} isolates with a gene in the \textit{bla\textsubscript{CTX-M-1}}-group has carried \textit{bla\textsubscript{CTX-M-1}} and isolates with a gene in the \textit{bla\textsubscript{SHV}}-group has carried the \textit{bla\textsubscript{SHV-12}} \cite{2, 3, 6}.

When assessed on shipment level, the type of genes encoding ESBL- or AmpC have varied over the years (Table 1). However, in the majority of the shipments...
positive for ESBL- or pAmpC-producing *E. coli* (30/43), all the isolates carried a gene in the *bla*CMY-2-gene group.

The exact reasons for the decrease of ESBL- or pAmpC-producing *E. coli* in imported breeding stocks remain unsolved. On the discovery of ESBL- or pAmpC-producing *E. coli* in traded breeders in 2010, discussions between the international companies providing breeders, SPMA and the Swedish companies buying the breeders were initiated by SPMA. Since 2010, the situation regarding ESBL- or pAmpC-producing *E. coli* in the broiler production and potential measures to improve the situation have been discussed regularly between experts from SVA and the Swedish stakeholders, and with the international breeding companies. Possibly, this dialogue that included requests by the Swedish companies that acquired breeders should be free from ESBL/pAmpC-producing *E. coli* and feedback on results have contributed to motivate and encourage the international companies to work towards reducing the occurrence among breeders. The exact measures taken by the international breeding companies are not known to us, except that the previously reported off-label use of cephalosporins at breeder hatcheries has ceased. However, the Swedish breeder companies have requested that cephalosporins should never be used for breeders intended for the Swedish market and hence it is unlikely that any direct selection pressure has been present in those animals.

In conclusion, monitoring of *E. coli* with resistance to extended spectrum cephalosporins in broilers and breeders using selective methods disclosed high occurrence of such bacteria in Swedish broiler production due to transmission from the top of the breeding pyramid. These data underpinned the need to stop transmission by management changes, and that was likely implemented by the broiler industry at the higher levels of the breeding pyramid. Furthermore, the continued monitoring of *E. coli* with resistance to extended spectrum cephalosporins has provided direct feedback on the result of any management changes. The decreased occurrence of ESBL- or pAmpC-producing *E. coli* among breeders is most likely the main reason for the consequent decrease in the occurrence of ESBL- or pAmpC-producing *E. coli* among broilers in Sweden (Fig. 1).

**Table 1** Number of shipments positive for ESBL- or pAmpC-producing *E. coli* in total each year per gene groups detected in each shipment

| Year | No. of shipments | No. of positive shipments | No. of positive shipments per *bla*-gene group |
|------|-----------------|--------------------------|---------------------------------------------|
|      |                 |                          | CIT | CTX-M-1 | SHV | CTX-M-1+CIT | CIT+SHV | CTX-M-1+SHV | ND |
| 2010 | 5               | 3                        | 3   |        |     |            |        |             |    |
| 2011 | 8               | 8                        | 8   |        |     |            |        |             |    |
| 2012 | 9               | 5                        | 3   |        |     |            |        |             |    |
| 2013 | 10              | 4                        | 1   | 2      |     |            |        |             | 2  |
| 2014 | 12              | 5                        | 3   | 1      |     |            |        |             |    |
| 2015 | 16              | 13                       | 9   | 3      |     |            |        |             |    |
| 2016 | 16              | 4                        | 2   | 1      |     |            |        |             |    |
| 2017 | 15              | 1                        |     |        |     |            |        |             |    |
| 2018 | 16              | 0                        |     |        |     |            |        |             |    |
| 2019 | 15              | 0                        |     |        |     |            |        |             |    |

*Not determined: The isolates from these shipments where lost and not available for confirmation. The occurrence of pAmpC-producing *E. coli* carrying genes belonging to the *bla*CMY-2-gene group in the birds from these shipments has been confirmed in subsequent sampling with boot swabs in these flocks (data not shown)*

**Abbreviations**
ESBL: Extended-spectrum beta-lactamases; EFSA: European Food Safety Authority; pAmpC: Plasmid mediated AmpC; SPMA: Swedish Poultry Meat Association; SVA: National Veterinary Institute, Sweden.

**Acknowledgements**
The breeding companies in Sweden are acknowledged for performing the sampling of imported breeders.

**Prior publication**
Data have not been published previously.

**Authors’ contributions**
ON, AL, CG and BB designed the original monitoring, SB and AL performed laboratory analysis, ON and SB analysed the results, ON drafted the manuscript and all authors contributed with constructive discussions and revising of the manuscript. All authors read and approved the final manuscript.

**Funding**
The surveillance of ESBL- or pAmpC-producing *E. coli* among breeder breeders has been funded by Grants from the Swedish Board of Agriculture (Dnr 6.2.18–14284/2018) but they have not been involved in the study design or the writing of the manuscript. It was also co-financed by the National Veterinary Institute (SVA), Uppsala, Sweden. Open access funding provided by Linköping University.

**Availability of data and materials**
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Ethics approval and consent to participate
This study did not require official or institutional ethical approval. The animals were handled according to high ethical standards and national legislation.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests. The data have been discussed with the breeding companies and the SPMA and they have been informed about, but have not had any influence on, the content of the manuscript.

Author details
1 Department of Animal Health and Antimicrobial Strategies, National Veterinary Institute (SVA), 751 89 Uppsala, Sweden. 2 Department of Biomedical and Clinical Sciences, Linköping University, Linköping 58183, Sweden.

Received: 10 February 2020 Accepted: 15 June 2020
Published online: 22 June 2020

References
1. Mughini-Gras L, Dorado-Garcia A, van Duijkeren E, van den Bunt G, Dierikx CM, Bonten MJM, et al. Attributable sources of community-acquired carriage of Escherichia coli containing beta-lactam antibiotic resistance genes: a population-based modelling study. Lancet Planet Health. 2019;3:e357–e369.
2. Borjesson S, Ny S, Egervarn M, Bergstrom J, Rosengren A, Englund S, et al. Limited dissemination of extended-spectrum beta-lactamase- and plasmid-encoded AmpC-producing Escherichia coli from food and farm animals. Sweden Emerg Infect Dis. 2016;22:634–40.
3. Svarm. Swedish Veterinary Antimicrobial Resistance Monitoring. ISSN 1650–6332. https://www.sva.se/en/our-topics/antibiotics/svarm-resistance-monitoring/swedres-svarm-reports/ (all Svarm reports, 12 June 2020, date last accessed).
4. Bortolaia V, Bisgaard M, Bojesen AM. Distribution and possible transmission of ampicillin- and nalidixic acid-resistant Escherichia coli within the broiler industry. Vet Microbiol. 2010;142:379–86.
5. Petersen A, Christensen JP, Kuhnert P, Bisgaard M, Olsen JE. Vertical transmission of a fluoroquinolone-resistant Escherichia coli within an integrated broiler operation. Vet Microbiol. 2006;116:120–8.
6. Nilsson O, Borjesson S, Landen A, Bengtsson B. Vertical transmission of Escherichia coli carrying plasmid-mediated AmpC (pAmpC) through the broiler production pyramid. J Antimicrob Chemother. 2014;69:1497–500.
7. Dierikx CM, van der Goot JA, Smith HE, Kant A, Mevius DJ. Presence of ESBL/AmpC-producing Escherichia coli in the broiler production pyramid: a descriptive study. PLoS ONE. 2013;8:e79005.
8. Agero Y, Jensen JD, Hassman H, Pedersen K. Spread of extended spectrum cephalosporinase-producing Escherichia coli clones and plasmids from parent animals to broilers and to broiler meat in a production without use of cephalosporins. Foodborne Pathog Dis. 2014;11:740–6.
9. Mo SS, Norstrom M, Slettemeas JS, Lovland A, Urdaill AM, Sunde M. Emergence of AmpC-producing Escherichia coli in the broiler production chain in a country with a low antimicrobial usage profile. Vet Microbiol. 2014;171:315–20.
10. Apostolakos I, Mughini-Gras L, Fasolato L, Piccirillo A. Assessing the occurrence and transfer dynamics of ESBL/pAmpC-producing Escherichia coli across the broiler production pyramid. PLoS ONE. 2019;14:e0217174.
11. Perez-Perez FJ, Hanson ND. Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol. 2002;40:2153–62.
12. Woodford N, Fagan EJ, Ellington MJ. Multiplex PCR for rapid detection of genes encoding CTX-M extended-spectrum (beta)-lactamases. J Antimicrob Chemother. 2006;57:154–5.
13. Fang H, Ataker F, Hedin G, Dornbusch K. Molecular epidemiology of extended-spectrum beta-lactamases among Escherichia coli isolates collected in a Swedish hospital and its associated health care facilities from 2001 to 2006. J Clin Microbiol. 2008;46:707–12.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.